

# Microbial Contamination of the Traditional Medicine Used by the *Pnar* Tribe of Meghalaya, India

Diamond Salahe<sup>1</sup>, Dibyendu Paul<sup>2</sup>

Department of Environmental Studies, North-Eastern Hill University, Shillong 793022, India<sup>1-2</sup>

**Abstract:** This study examined microbial contamination in herbal medicinal products in Jaintia Hills Districts, Meghalaya, India. Analysis of 40 samples revealed widespread bacterial and fungal growth, exceeding safety limits in 30% of samples. Also, Aerobic bacteria counts ranged from  $64 \times 10^5$  to  $130 \times 10^6$  CFU/g, surpassing WHO and Ayurveda Pharmacopeia of India guidelines. Similarly, 87.5% of samples showed significant fungal growth, with 12.5% exceeding safety limits. Bacterial analysis revealed *E. coli* (35%) which indicates fecal contamination and poor hygiene. *S. aureus* (53%) suggests poor handling and preparation practices. *P. aeruginosa* (20%) is another indicator of poor hygiene and potential contamination. The presence of these pathogens in herbal products is a serious concern globally, and it's crucial to address this issue to ensure consumer safety. The three pathogens *E. coli*, *S. aureus* and *P. aeruginosa* can cause a range of health problems, from mild to severe, including gastrointestinal issues (diarrhea, vomiting, abdominal pain), skin and wound infections, respiratory problems (pneumonia, bronchitis), life-threatening conditions (sepsis, meningitis, urinary tract infections).

**Keywords:** Herbal Medicinal Products (HMPs), World Health Organization (WHO), *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, Total viable count (TVC), Colony forming units (CFU), Jaintia Hills Districts, Meghalaya, India

## I. INTRODUCTION

The World Health Organization's (WHO) definition of Herbal Medicinal Products (HMPs). HMPs are medicinal products that contain only herbal drugs or herbal drug preparations as active ingredients. Herbal drugs refer to raw materials, such as plants, used for medicinal purposes. Herbal drug preparations include processed herbal materials, like extracts, tinctures, or powders. Mixed seasoning products are blends of multiple herbs. Excipients, like binders or fillers, may be added to HMPs to enhance their absorption or stability. Traditional herbal remedies may include non-plant materials like animal or mineral substances in certain regions. However, products containing chemically defined active substances, artificial compounds, and isolated constituents from herbs (like isolated alkaloids or glycosides) are not classified as herbal products according to the WHO definition [48].

Despite the clear definition and framework for herbal medicinal products, the industry still faces significant challenges, particularly when it comes to microbial contamination. This contamination can lead to compromised product quality and reduced competitiveness in international markets [24]. The definition of contamination provided highlights the various ways in which herbal products can become contaminated, including chemical impurities, microbiological contaminants (such as bacteria, fungi, or viruses), and foreign matter (such as heavy metals or other substances) [26].

This contamination can occur at any stage of production, including starting materials (e.g., raw herbs), intermediate products (e.g., extracts or powders), finished products (e.g., capsules or tablets), sampling, packaging, or repackaging or storage or transport. The introduction of microorganisms in herbal medicinal products can alter the physicochemical characteristics of the product, which may lead to harmful effects on the quality of the herbal medicinal products [10].

The sources of contamination in the herbal medicinal products are as follows

- i) Environmental conditions in which the medicinal plants are grown or collected.
- ii) Drying and processing conditions of the herbal medicinal products.
- iii) The conditions under which the herbal medicinal products are stored and transported.
- iv) Insanitary utilization of herbal medicinal products by the patients.
- v) The manufacturing procedures, when the ready-made herbal medicinal products are prepared [11, 20].

Herbal products can be contaminated with various substances, including pesticides, toxic metals, and microorganisms. The main microorganisms found in herbal products are, *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhi*, and *Pseudomonas aeruginosa*. Studies have shown that bacterial contamination is a significant problem in traditional medicine samples, highlighting the need for strict quality control measures. Fungal contamination, particularly with *Aspergillus* and *Penicillium* species, is also a significant concern due to the potential production of mycotoxins. Consuming contaminated traditional medicines can lead to chronic health issues, such as liver damage, kidney damage, immune system suppression and cancer. [46,49]. Consuming herbal products contaminated with microorganisms like *E. coli* can lead to serious health issues. *E. coli* is a type of bacteria that is commonly found in the large intestine of humans and warm-blooded animals. While most *E. coli* strains are harmless and do not cause disease in healthy individuals, some pathogenic strains can cause a range of diseases, including intestinal diseases such as diarrhea, urinary tract infections, inflammatory bowel disease, extra-intestinal diseases such as pneumonia, meningitis, and sepsis. These diseases can affect both healthy individuals and those with compromised immune systems, such as the elderly, young children, and people with chronic illnesses [15 and 39]. The genus *Escherichia* was named after Theodor Escherich, *E. coli* is a facultative anaerobic Gram-negative bacillus, belonging to the family Enterobacteriaceae. *E. coli* strains can become pathogenic when they acquire certain genetic material, such as virulence factors, which enable them to cause disease. Virulent strains of *E. coli* can cause a range of serious infections, including gastroenteritis (diarrheal disease), urinary tract infections (UTIs), neonatal meningitis (infection of the lining of the brain and spinal cord in newborns), peritonitis (inflammation of the lining of the abdominal cavity), mastitis (infection of the breast tissue), gram-negative pneumonia (lung infection), septicemia (bloodstream infection), hemolytic-uremic syndrome (a potentially life-threatening condition that can cause kidney failure and anemia) [11].

Alexander Ogston and Louis Pasteur first described "micrococci" isolated from furuncles and abscesses in 1880. "Staphyle" (Greek: σταφυλή) meaning "bunch of grapes" (likely due to the cluster-like appearance of the bacteria), "Coccus" (Greek: κόκκος) meaning "round-shaped" (referring to the bacteria's spherical shape) and "Aureus" (Latin: aureus) meaning "golden" (due to the characteristic orange-yellow color of the colonies on agar plates). The temperature growth range of *S. aureus* is 7°C - 48.5°C, optimum growth temperature is 30 °C - 37° C. This information helps us understand the growth conditions and characteristics of *S. aureus*, which is an important pathogen in human medicine. Alterations in temperature during the storage of herbal medicinal products can create an environment conducive to the growth of *S. aureus*. Additionally, *S. aureus* can thrive in a wide range of pH conditions, from 4.2 to 9.3, with an optimum pH range of 7-7.5. This adaptability makes *S. aureus* a resilient and potentially problematic contaminant in herbal products. Alterations in pH during the manufacturing process can create an environment conducive to the growth of *S. aureus* in herbal medicinal products. *S. aureus* is a highly adaptable and opportunistic pathogen that can cause a wide range of diseases, including localized skin and soft-tissue infections (e.g., abscesses, furuncles, cellulitis), life-threatening septicemia (bloodstream infection), bloodstream infections (bacteremia), pneumonia, meningitis, osteomyelitis (bone infection), endocarditis (heart valve infection) [15].

*Pseudomonas* is a tremendously versatile Gram-negative bacterium with the ability to flourish in a broad spectrum of environments. *Pseudomonas aeruginosa* can cause urinary tract infections, respiratory tract infections, bacteremia, dermatitis, bone and joint infections, soft tissue infections, GI infections etc [21]. Several studies have been done around the world to analyze the microbial content of herbal medicines in Thailand [23], Nigeria [4, 7, 25 and 9], Kenya [22, 19], Bangladesh [28, 2], Ghana [36, 13], Iran [27] India [43, 8, 17 and 34, 33, 35]

## II. METHODOLOGY

### A. Study area.

The present study was conducted in thirty-one villages spread throughout the Jaintia Hills District of Meghalaya, India (Fig 1). Selection of the study area was based on the availability of traditional healers in these villages and their willingness to share their medicines for analysis. The Jaintia Hills (located at latitude-25.4, longitude-92.1) are composed of two districts viz., East Jaintia Hills District and West Jaintia Hills District East Jaintia Hills Districts located at the easternmost part of Meghalaya and cover an area of 2040 sq. km.

It is bounded by Bangladesh in the south, North Cachar Hills district in the east and West Jaintia Hills district in the north and west. West Jaintia Hills District is bounded by Assam in the North, Bangladesh and East Jaintia Hills District in the South, Assam in the East and East Khasi Hills District in the West. The total population of Jaintia Hills is 3, 95,124 [6].




Fig. 1-Location map of Jauntia hills showing the study villages

**B. Sample Collection and Preparation for Laboratory Analysis.**

Lots sizes of approximately 15 - 20 g for each product purchased were taken and packed aseptically in sterile zipped polythene bags. In the laboratory, sample containers were opened under aseptic conditions and 1 g of product was placed into a sterile container containing sterile Buffered Sodium Chloride-Peptone Solution pH 7.0, and the volume was adjusted to 10 ml. Then, 1 ml of the prepared homogenate inoculum obtained by vortex was transferred into a test tube containing 9 ml of sterile physiological saline. The procedure was repeated up to 6 serial dilutions and in the last dilution 1 ml of inoculum was discarded [47].

**B. Determination of total viable counts.**

*Plate count for bacteria:* The samples for total viable colony (TVC) count determination were the serially diluted specimens in sterile physiological normal saline in the  $10^{-1}$  to  $10^{-10}$  dilutions. Using a sterile pipette, 1 ml of each dilution was inoculated into Nutrient Agar (NA) plate in triplicate. The plates were incubated at 37°C for 24 hours ( $\pm 3$  hours). Colony counts were done by taking 300 colonies per plate as the maximum consistent with good evaluation [47]. The colony forming units (cfu)/g or (cfu)/ ml were calculated as follows,

CFU/ml – (Number of colonies  $\times$  dilution factor) / volume of culture plate [30]

*Plate count for fungi:* For fungi, the same serial dilution method as for bacteria was followed but Potato Dextrose Agar with antibiotics was used in place of Nutrient agar and the plates were incubated at 20<sup>0</sup> to 25<sup>0</sup> C for 5 days unless a more reliable count was obtained in a shorter time. The Colony Forming Units were calculated using plates with not more than 100 colonies [47].

**C. Isolation and identification of *Escherichia coli*.**

Having dissolved 1 g of the preparation being examined using lactose broth the volume was adjusted to 10 ml with the same medium. 90 ml of nutrient medium was inoculated with a quantity of the solution, thus obtained containing 1 g or 1 ml of the preparation being examined. The mixture was incubated at 35<sup>0</sup>C to 37<sup>0</sup>C for 24 to 48 hours. Isolation of *Escherichia coli* was achieved by streaking the pre-enriched culture from nutrient medium onto MacConkey agar plates to obtain pure colonies The plates were inverted and incubated at 44.5°C for 24 to 48 hours. *E. coli* on MacConkey agar appeared bright pinky-red in color. Presumptive *E. coli* colonies were identified at the species level by Gram staining and IMViC tests [47].

**D. Isolation and identification of *Staphylococcus aureus*:**

1 g of the sample being examined was dissolved using lactose broth in place of buffered sodium chloride-peptone solution, and the volume was adjusted to 10 ml with the same medium. 90 ml of soybean-casein digest medium was inoculated with a quantity of the solution, thus obtained containing 1 g or 1 ml of the preparation being examined. The mixture was incubated at 35<sup>0</sup>C to 37<sup>0</sup>C for 24 to 48 hours. Isolation of the *S. aureus* was achieved by streaking the pre-enriched culture from soybean-casein digest onto selective differential agar plates of freshly prepared Mannitol Salt Agar (MSA); a selective and differential medium used for the isolation of pathogenic staphylococci. The plates were incubated at 37°C for 18 to 24 hours under aerobic conditions. Colonies showing golden yellow color or colorless were presumed to be *Staphylococcus* spp. On MSA, pathogenic *S. aureus* produces small colonies surrounded by yellow zones as a result of mannitol sugar fermentation. If, upon examination of the incubated plates, none of them contained colonies having the characteristics for the media used, the sample met the requirements for the absence of *Staphylococcus aureus*. The presumptive colonies were subcultured onto nutrient agar for purification and masking the effect of acid produced during the fermentation of MSA. The colonies selected from nutrient agar were subjected to Gram stain, to check the morphology and staining characteristics. The gram-positive cocci organisms were subjected to a catalase test to differentiate between *Staphylococcus* spp. and *Streptococcus* spp. Catalase-positive colonies were further subjected to coagulase and deoxyribonuclease tests. If bubbles appear (due to the production of oxygen gas) the bacteria are catalase-positive. If no bubbles appear, the bacteria are catalase-negative. For deoxyribonuclease tests, if a clear zone is observed around the colony on the Dnase Agar plate, the organism is positive. The material passes the test if cultures of the type described do not appear or if the confirmatory biochemical test is negative [47].

**E. Isolation and identification of *Pseudomonas aeruginosa*.**

Having dissolved 1 g of the sample being examined using lactose broth the volume was adjusted to 10 ml with the same medium. 90 ml of soybean-casein digest medium was inoculated with a quantity of the solution, thus obtained containing 1 g or 1 ml of the preparation being examined. The mixture was incubated at 35<sup>0</sup> C to 37<sup>0</sup> C for 24 to 48 hours. The medium was examined for growth, if growth was present, a portion of the medium was streaked on the surface of the cetrimide agar medium, covered, and incubated at 35<sup>0</sup> C to 37<sup>0</sup> C for 18 to 24 hours. Colonies showing greenish coloration under UV light and on Gram staining appeared to be Negative rod-shaped bacilli were presumed to be *P. aeruginosa*.

The representative suspect colonies from cetrinide agar were streaked onto *Pseudomonas* Agar medium for the detection of fluorescein and the *Pseudomonas* agar medium for the detection of pyocyanin. The inoculated media were incubated at 33°C to 37°C for not less than 3 days. The streaked surfaces were examined under ultra-violet light to determine colonies which is blue for *Pseudomonas* agar medium for the detection of fluorescein and yellow for *Pseudomonas* agar medium for the detection of pyocyanin. If growth of suspect colonies occurs, 2 or 3 drops of a freshly prepared 1 per cent w/v solution of N,N,N1,N1-tetramethyl-4-phenylenediamine dihydrochloride on filter paper were smear with the colony; if there is development of a pink color, changing to purple, the sample is positive for *P. aeruginosa*. If there is no development of a pink color, changing to purple, the sample meets the requirements of the test for the absence of *Pseudomonas aeruginosa* [47].

### III. RESULTS AND DISCUSSIONS

#### A. Total viable count.

Among the 40 samples examined, all displayed observable bacterial growth, regardless of contamination thresholds. Of these, 30% exceeded the safety limits established by WHO guidelines and the Ayurveda Pharmacopeia of India, with aerobic bacteria counts ranging from  $64 \times 10^5$  to  $130 \times 10^6$  CFU/g. 87.5% of the samples displayed noticeable fungal growth, regardless of acceptable contamination levels. Among them, 12.5% exceeded the safety thresholds for fungal growth (CFU/g  $\leq$  103), with counts ranging from  $32 \times 10^3$  to  $98 \times 10^4$  CFU/g. Similar results have been reported around the world where the herbal medicines exceeded the established by WHO and or different agencies like Nigeria [4 and 7], Thailand [23], Iran [27], Ghana [36], Bangladesh [28] Kenya [22,19]. In India, several studies have been reported on the contamination of herbal medicines whose results for bacterial and fungal viable count were similar to this study's findings [33- 35, 17, 50, 16]. Microscopic analysis suggested fungal contamination that was similar to another study that demonstrated the presence of fungal species known to be able to produce mycotoxins, such as *Aspergillus niger*, *Aspergillus flavus* and *Aspergillus parasiticus* [1]. Many studies have also demonstrated the presence of mycotoxins in preparations derived from medicinal plants [3]. Characterization of fungal colonies, although not required by the WHO standards [47], is important in assessing the risk of analyzing products.

#### B. Determination of specific microorganisms.

A prevalence rate of 35%, 53 %, and 20% for *E. coli*, *S. aureus*, and *P. aeruginosa* respectively was recorded. Out of the 40 samples examined, *E. coli* was detected in 14 samples, *S. aureus* was found to be present in 21 samples and *P. aeruginosa* was detected in 8 samples. Several studies have been conducted around the world where the evaluation of *E. coli*, *S. aureus* and *P. aeruginosa* is done for example in Thailand [23], in Nigeria [7] and Iran (27) reported similar results to these study findings. In India, Bais et al., showed the presence of *E. coli*, *S. aureus*, and *P. aeruginosa* [34]. Evaluation of the microbiological quality of hepatoprotective herbal formulations of various brands marketed in Yavatmal, India showed the presence of *E. coli* in 4 samples, *S. aureus* in 3 samples and *P. aeruginosa* in 4 samples [33] Another study done to determine the presence of microbial content in the Ashwagandha indicates the presence of *E. coli* in 3 samples, *S. aureus* in 4 samples and *P. aeruginosa* [35]. In a study conducted in Trychi City, Tamil Nadu, the samples were found to be contaminated with more than one bacterial pathogen such as *S. aureus*, *E. coli*, *P. aeruginosa*, *Shigella* sp and *Salmonella* sp. [17]. However, contradicting the findings of this study, a study conducted in Meerut, India reported that the herbal medicines were not contaminated with *S. aureus*, *E. coli*, or *P. aeruginosa* [8]. Factors contributing to microbial contamination in TMPs: exposure to a polluted environment, inadequate handling of raw materials, substandard packaging, use of contaminated containers, and harvesting from polluted surroundings (14). *Escherichia coli* is a bacterium commonly inhabiting the lower intestine of warm-blooded animals. While many *E. coli* strains are harmless, certain types can induce severe food poisoning. Shiga toxin-producing *E. coli* (STEC) is a strain capable of causing significant foodborne illness. Although most cases resolve on their own, some instances can progress to life-threatening conditions like hemolytic uremic syndrome (HUS), particularly affecting young children and the elderly (WHO 2018). The presence of *E. coli*, an intestinal bacterium, indicates contamination by feces in the production line, revealing poor hygiene during the preparation and storage of these herbal medicines [5, 29]. *Staphylococcus aureus* the most predominant bacteria isolated from contaminated samples is a normal flora of the nasal passage and skin, however, their presence in herbal preparations to be ingested orally may result in food poisoning and gastro-intestinal infection (51). *Staphylococcus aureus* ranks among the most prevalent bacterial infections in humans, responsible for a plethora of ailments including bacteremia, infective endocarditis, various skin and soft tissue infections (such as impetigo, folliculitis, furuncles, carbuncles, cellulitis, scalded skin syndrome, and others), osteomyelitis, septic arthritis, infections related to prosthetic devices, pulmonary infections (like pneumonia and empyema), gastroenteritis, meningitis, toxic shock syndrome, and urinary tract infections [37, 40]. The severity and nature of the infection hinge on the strain of the bacterium and the site of invasion, potentially leading to invasive infections and/or diseases mediated by toxins [37, 12]. The pathophysiology exhibits considerable diversity contingent upon the specific type of *S. aureus* infection [37].

Tactics employed by these bacteria to evade the host immune response encompass the production of an antiphagocytic capsule, sequestration of host antibodies, antigen masking facilitated by Protein A, biofilm formation, intracellular survival, and inhibition of leukocyte chemotaxis [41 and 40]. *Pseudomonas aeruginosa* is a soil-derived bacterium implicated in urinary tract and respiratory infections. Its presence suggests improper washing and handling of herbs [29]. It notably affects patients with conditions such as burn wounds, cystic fibrosis, acute leukemia, organ transplants, and intravenous drug addiction. This bacterium commonly contaminates healthcare settings, leading to outbreaks traced back to various hospital items. Extended hospital stays often result in colonization by *P. aeruginosa*, heightening the risk of infection. Severe cases can manifest as malignant external otitis, endophthalmitis, endocarditis, meningitis, pneumonia, or septicemia. Recovery prospects correlate with the severity of the patient's underlying condition. The introduction of antipseudomonal aminoglycosides and penicillins has significantly improved prognosis, particularly ticarcillin and carbenicillin for neutropenic patients. Prompt initiation of therapy is crucial for optimal outcomes. Recent years have witnessed the introduction of new drugs with antipseudomonal activity, including penicillins, cephalosporins, and other  $\beta$ -lactams, presenting promising avenues for therapy in these infections [14]

#### IV. CONCLUSION

In conclusion, the assessment of microbial contamination in herbal medicinal products across various regions underscores the pervasive issue of compromised product quality and potential health risks associated with their consumption. Studies conducted in diverse geographic locations, including Nigeria, Thailand, Iran, Ghana, Bangladesh, Kenya, and India, consistently reveal alarming levels of bacterial and fungal contamination exceeding permissible limits. *Escherichia coli*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa* are among the frequently identified pathogens, indicating fecal contamination, poor hygiene during preparation, and inadequate storage conditions as contributing factors.

The presence of these microbial contaminants poses significant health hazards, ranging from mild gastrointestinal discomfort to life-threatening conditions like food poisoning, septicemia, and systemic infections, especially in vulnerable populations such as children and the elderly. Additionally, the diversity of bacterial and fungal species detected underscores the complexity of the contamination issue and the need for comprehensive mitigation strategies. Efforts to improve herbal product quality must address multiple facets of the production and supply chain, including sourcing of raw materials, manufacturing processes, packaging, and storage conditions. Regulatory authorities need to enforce stringent quality control measures, including adherence to international pharmacopoeial standards, to ensure the safety and efficacy of herbal medicines.

#### ACKNOWLEDGMENTS

The authors are grateful to the Traditional Healers for providing the samples and permission to publish the findings of this study. The authors are thankful to the Department of Environmental Studies, North Eastern Hill University, Shillong for providing the necessary facilities for conducting the study. The author (**Diamond Salahe**) is thankful to the Ministry of Tribal Affairs, Government of India for providing the National Fellowship for ST (Award letter: 201819-NFST-MEG-01293).

#### DECLARATIONS

List of abbreviations: Not applicable.

Ethical approval and consent to participate: This study was undertaken with the approval of the Local Traditional Healer of Jaintia Hills of Meghalaya, northeast India.

Consent for publication: Not applicable

Conflict of interest: The authors have no conflicts of interest to disclose.

Funding: This study has not received any grant/funding from any agencies or forum.

Author contributions: DS and DP conceived the idea and designed the collection of samples. DS conducted a collection of samples and experiments. DS and DP wrote the manuscript. All authors have read and approved the final version of the manuscript.

**REFERENCES**

- [1]. A.A.G. Candlish, S.M. Pearson, K.E. Aidoo, J.E. Smith, B. Kelly and H. Irvine, "A survey of ethnic foods for microbial quality and aflatoxin content", *Food Additives and Contaminants.*, vol.18, no.2, pp. 129-136, 2001.
- [2]. A.M. Islam, M.F. Khalik, N. Uddin, M.S. Hossain, M.M. Hossain, M.M. Hasan, S.M. Fahad and P. Saha, "Evaluation of microbiological and physicochemical profile of some herbal preparations manufactured by pharmaceutical and herbal manufacturers in Bangladesh", *Journal of Pharmaceutical Investigation.*, vol. 45, no. 2, pp.223-235, 2015.
- [3]. C.M. de Sousa Lima, M.A.T. Fujishima, B. de Paula Lima, P.C. Mastroianni, F.F.O. de Sousa and J.O. da Silva, "Microbial contamination in herbal medicines: a serious health hazard to elderly consumers", *BMC Complementary Medicine and Therapies.*, vol. 20, no.1, pp. 17, 2020.
- [4]. C.O. Esimone, K.F. Chah and S.C. Ikejide, "Microbiological quality of herbal preparations marketed in South East Nigeria", *Journal of Natural Remedies.*, vol.2, no.1, pp. 42-8, 2002.
- [5]. C.O. Esimone, P.O. Oleghe, E.C. Ibezim, C.O. Okeh and I.R. Iroha, "Susceptibility- resistance profile of microorganisms isolated from herbal medicine products sold in Nigeria", *African Journal of Biotechnology.*, vol.6, no.24, pp. 2766-2775, 2007.
- [6]. Census of India, Provisional Population Totals: Meghalaya, Office of the Registrar General and Census Commissioner, India, 2011, Available at [http://censusindia.gov.in/2011-prov-results/prov\\_data\\_products\\_meghalaya.html](http://censusindia.gov.in/2011-prov-results/prov_data_products_meghalaya.html).
- [7]. D. Abba, H. Inabo, S. Yakubu and O. Olonitola, "Contamination of herbal medicinal products marketed in Kaduna metropolis with selected pathogenic bacteria", *African Journal of Traditional, Complementary and Alternative Medicines.*, vol. 6, no.1, 2009.
- [8]. D.K. Gupta, R.D. Sharma, R.I. Gupta, S. Tyagi and K.K. Sharma, "Evaluation of some herbal solid dosage forms for microbial contamination", *International Journal Pharm Pharm Science.*, vol.4, no.4, pp.261-3, 2012.
- [9]. E.J. Archibong, C.N. Igboeli, N.C. Okoro and I. Obika, "Microbiological Assessment of some liquid herbal medications sold in Awka metropolis, Anambra state", *Bioengineering and Bioscience.*, vol. 5, no. 3, pp. 37-46, 2017.
- [10]. European Medicines Agency Science Medicines Health, "Refection paper on microbiological aspects of herbal medicinal products and traditional herbal medicinal products", 2015.
- [11]. F.H. Shaikh, A.K. Salunkhe, S. S. Kadam, "An outlook towards the Microbial Quality of Marketed Herbal Medicinal formulations", *American Journal of PharmTech Research.*, vol. 9, no. 2, pp. 171-187. 2019.
- [12]. F.R. DeLeo, B.A. Diep and M. Otto, "Host defense and pathogenesis in Staphylococcus aureus infections", *Infectious Disease Clinics of North America.*, vol.23, no.1, pp. 17-34, 2009.
- [13]. G. Osei-Adjei, H.K. Hackman, F.C. Mills-Robertson and S.C. Tay, "Quality assessment of aqueous herbal/medicinal products sold on the Ghanaian market", *Food Science and Quality Management.*, vol. 20, pp.13-18, 2013.
- [14]. G. P. Bodey, R. Bolivar, V. Fainstein and L. Jadeja, "Infections Caused by Pseudomonas aeruginosa", *Reviews of Infectious Diseases.*, vol. 5, no.2, pp. 279-313, 1983.
- [15]. G.B. Raho and B. Abouni, "Escherichia coli and Staphylococcus aureus most common source of infection", *The Battle against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs*, A. Méndez-Vilas, Ed., pp. 637-648, 2015.
- [16]. H. Chandra, P. Kumari and S. Yadav, "Evaluation of aflatoxin contamination in crude medicinal plants used for the preparation of herbal medicine", *Oriental Pharmacy Experimental Medicine.*, vol.19, pp. 137-143, 2018.
- [17]. K. Rajapandiyam, S. Shanthi and S. Vidya, "Assessment of microbial quality in marketed herbal drugs sold in Trichy city", *International Journal of Pharmaceutical, Chemical & Biological Sciences.*, vol 3, no.3, pp.894-898, 2013.
- [18]. K.K. Rana and S. Rana, "Review on present status and future of herbal medicine", *The Beats of Natural Science.*, vol.1, no.2, pp. 1-8, 2014.
- [19]. L. Keter, R. Too, N. Mwikwabe, S. Ndwigah, J. Orwa, E. Mwamburi, R. Korir and C Mutai, "Bacteria contaminants and their antibiotic sensitivity from selected herbal medicinal products from Eldoret and Mombasa, Kenya", *Current Research in Microbiology.*, vol. 7, no.1, pp.18-28, 2016.
- [20]. M. Bhairam, A. Roy, S. Bahadur, A. Banafar and D. Turkane, "Standardization of herbal medicines—an overview", *Journal of Applied Pharmaceutical Research.*, vol.1, no.1, pp. 14-21, 2013.
- [21]. M. Juhas et al., "Pseudomonas aeruginosa essentials: an update on investigation of essential genes", *Microbiology.*, vol.1, no.161, no.11, pp.2053-60, 2015.
- [22]. M.O. Onyambu, H.K. Chepkwony, G.N. Thoithi, G.O. Ouya and G.O. Osanjo, "Microbial quality of unregulated herbal medicinal products in Kenya", *African Journal of Pharmacology and Therapeutics.*, vol. 2, no.3, 2013.

- [23]. M.T. Chomnawang, P. Paojinda, N. Narknopmnee and L.R. Yingyod, "Evaluation of microbiological quality of herbal products in Thailand", *Thai Journal of Phytopharmacy*, vol.10 no. 2, 2003.
- [24]. N. Garg and P.C. Gupta, "Irradiation: A technique for microbial decontamination of medicinal plants", *Microbes in Food and Health.*, pp. 225-237, 2016.
- [25]. O.A. Igbeneghu and A. Lamikanra, "Assessment of the microbial quality of some oral liquid herbal medicines marketed in Ile-Ife, South-western Nigeria", *African Journal of Microbiology Research.*, vol. 10, no. 38, pp.1618-1624, 2016.
- [26]. P. Posadzki and E. E. Watson, "Contamination and adulteration of herbal medicinal products: An overview of systematic reviews", *European Journal of Clinical Pharmacology.*, vol.69, no.3, pp.295-307, 2013.
- [27]. R. Enayatifard, H. Asgarirad and B. Kazemi-Sani, "Microbial quality of some herbal solid dosage forms", *African Journal of Biotechnology.*, vol. 9, no.11, pp. 1701-1705, 2010.
- [28]. R. Noor, N. Huda, F. Rahman, T. Bashar and S.K. Munshi, "Microbial contamination in herbal medicines available in Bangladesh", *Bangladesh Medical Research Council Bulletin.*, vol. 39, no.3, pp. 124-9, 2013.
- [29]. S. Darkwah, D. Agbettor, F. Codjoe, E. Donkor, "Microbial Contamination of Herbal Preparations on the Ghanaian Market, Accra", *Microbiology Insights.*, vol. 15, 2022.
- [30]. S. Sieuwerts, F. A. M. de Bok, E. Mols, W. M. de Vos, J. E. T. van Hylckama Vlieg, "A simple and fast method for determining colony forming units", *Letters in Applied Microbiology.*, vol. 47, no. 4, pp. 275-278, 2008.
- [31]. S.A. Nirmal, S.C. Pal, S.O Otimenyin, A. Thanda, E. Mostafa, S.K. Kundu, R.A Thandavarayan and S.C Mandal, "Contribution of herbal products in global market", *The Pharma Rev.*, pp. 95-104, 2013.
- [32]. S.A. Nirmal, S.C. Pal, S.O Otimenyin, A. Thanda, E. Mostafa, S.K. Kundu, R.A Thandavarayan and S.C Mandal, "Contribution of herbal products in global market", *The Pharma Rev.*, pp. 95-104, 2013.
- [33]. S.K. Bais and A.V. Chandewar, "Comparative evaluation of microbiological quality of hepatoprotective herbal formulations marketed in Yavatmal district of India", *International Journal of Advances in Pharmaceutical Analysis.*, vol. 4, no.2, pp. 44-46, 2014.
- [34]. S.K. Bais and A.V. Chandewar, "Comparative evaluation of microbiological quality of Antidiabetic Churna marketed in India", *Inventi Rapid: Ethnopharmacology.*, 2012.
- [35]. S.K. Bais, A.V. Chandewar, S.M. Charjan and D.W. Wargantiwar, "Comparative evaluation of microbiological qualities of Ashwagandha formulations marketed in Yavatmal district in India", *SOJ Pharmacy and Pharmaceutical Sciences.*, vol. 2, no.3, pp. 1-3, 2015.
- [36]. S.T. Odonkor, J. Osei, A.K. Anim, C. Laar and M. Okyere, "Microbiological quality of some herbal medicinal products sold in Accra, Ghana", *Elixir Pharmacy.*, vol. 40, pp. 5499-5503, 2011.
- [37]. S.Y. Tong, J.S. Davis, E. Eichenberger, T.L. Holland and V.G. Fowler, "Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management", *Clinical Microbiology Reviews.*, vol. 28, no.3, pp. 603-61, 2015. A.
- [38]. A. Sharma, C. Shanker, L.K Tyagi, M. Singh and C.V Rao, "Herbal medicine for market potential in India: An Overview", *Academic Journal of Plant Science.*, vol.1, no.2, pp. 26-36, 2008.
- [39]. T.A. Gomes, W.P. Elias, I.C. Scaletsky, B.E Guth, J.F. Rodrigues, R.M. Piazza, L.C. Ferreira and M.B. Martinez, "Diarrheagenic Escherichia coli.", *Brazilian Journal of Microbiology.*, vol11, no. 47, pp. 3-30, 2016.
- [40]. T.A. Taylor and C.G. Unakal, "Staphylococcus aureus Infection", [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
- [41]. T.J. Foster et al., "Immune evasion by staphylococci", *Nature Review Microbiology.*, vol.3, no.12, pp. 948-58, 2005.
- [42]. T.P. Aneesh, M. Hisham, S. Sekhar, M. Madhu and T.V. Deepa, "International market scenario of traditional Indian herbal drugs-India declining", *International Journal of Green Pharmacy.*, vol.3, no. 3, pp. 184-190, 2009.
- [43]. V. Kalaiselvan, A.K. Shah, F.B. Patel, C.N. Shah, M. Kalaivani and A. Rajasekaran, "Quality assessment of different marketed brands of Dasamoolaristam, an Ayurvedic formulation", *International Journal of Ayurveda Research.*, vol.1, no.1, pp.10-13, 2010.
- [44]. V.A. Saran et al., "Current status of regulations for herbal medicines in Europe, United States and India", *Journal of Natura Conscientia.*, vol. 2, no.3, pp. 406, 2011.
- [45]. V.P. Kamboj et al., "Herbal medicine", *Current science.*, vol. 78, no. 1, pp. 35-9, 2000.
- [46]. World Health Organization, "Regulatory situation of herbal medicines: a worldwide review", Geneva: World Health Organization; 1998.
- [47]. H. Wang, Y Chen, L Wang, Q Liu, S Yang, C Wang "Advancing herbal medicine: enhancing product quality and safety through robust quality control practices" *Frontiers in Pharmacology*, vol. 14, 2023.
- [48]. World Health Organization, "WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues", World Health Organization., 2007.



- [49]. C. M de Sousa Lima<sup>1</sup>, M.A.T Fujishima<sup>1</sup>, B. de P. Lima, P. C. Mastroianni, F. F. O. de Sousa and J. O. da Silva<sup>1</sup>, “Microbial contamination in herbal medicines: a serious health hazard to elderly consumers” *BMC Complementary Medicine and Therapies.*, vol. 20, no. 17, 2020.
- [50]. N. Mukund, S Arun, D.G Kshirsagar, L. Pranjali, B.Shital, Q. Zeba, P Girishet “Investigation of Microbiological Aspects of Herbal Products Used In Ayurvedic Medicines and Estimation of Measurement Uncertainty” *Research Journal of Topical and Cosmetic Sciences.*, vol. 5, no. 2, pp. 46- 50, 2014.
- [51]. F. Guidi, A. Duranti, S. Gallina, Y. Nia, A Petruzzelli, A Romano, V Travaglini, A Olivastri, V Calvaresi, L Decastelli, et al. “Characterization of A Staphylococcal Food Poisoning Outbreak in A Workplace Canteen during the Post-Earthquake Reconstruction of Central Italy”. *Toxins.* vol.10 no.12 pp.5-23 2018.

TABLE I TOTAL VIABLE COUNT (TVC) OF THE TRADITIONAL MEDICINE PRODUCTS (TMPS) USED BY THE HEALERS OF JAINTIA HILLS DISTRICTS.

Sample no.	Bacteria							Fungi				
	10 <sup>-1</sup>	10 <sup>-2</sup>	10 <sup>-3</sup>	10 <sup>-4</sup>	10 <sup>-5</sup>	10 <sup>-6</sup>	CFU/g	10 <sup>-1</sup>	10 <sup>-2</sup>	10 <sup>-3</sup>	10 <sup>-4</sup>	CFU/g
1	TNT C	172.3 3	36.00	8.33	NIL	NIL	172.33×10 2	3	NIL	NIL	NI L	3×10 <sup>1</sup>
2	TNT C	TNT C	138.6 7	83.00	16.67	NIL	138.67×10 3	15.5	2.5	NIL	NI L	15.5×10 1
3	TNT C	TNT C	TNT C	TNT C	76.33	10.00	76.33×10 <sup>5</sup>	TNT C	TNT C	54	5.5	54×10 <sup>3</sup>
4	TNT C	TNT C	TNT C	TNT C	138.3 3	68.33	138.33×10 5	TNT C	TNT C	32	2.5	32×10 <sup>3</sup>
5	TNT C	TNT C	191.6 7	106.6 7	44.67	12.00	191.67×10 3	24	1	NIL	NI L	24×10 <sup>1</sup>
6	TNT C	TNT C	TNT C	TNT C	170.6 7	106.6 7	170.67×10 5	TNT C	TNT C	TNT C	26	26×10 <sup>4</sup>
7	TNT C	TNT C	TNT C	TNT C	TNT C	130.0 0	130.00×10 6	TNT C	TNT C	TNT C	80	80×10 <sup>4</sup>
8	TNT C	TNT C	161.6 7	55.00	13.00	NIL	161.67×10 3	125	26	2.5	1	125×10 1
9	TNT C	TNT C	198.6 7	161.6 7	132.0 0	94.00	198.67×10 3	TNT C	TNT C	TNT C	93	93×10 <sup>4</sup>
10	TNT C	TNT C	TNT C	53.00	28.00	6.33	53.00×10 <sup>4</sup>	TNT C	34	7	NI L	34×10 <sup>2</sup>
11	TNT C	TNT C	TNT C	177.0 0	32.33	NIL	177.00×10 4	49	10	1	NI L	49×10 <sup>1</sup>
12	TNT C	TNT C	166.3 3	64.33	9.00	NIL	166.33×10 3	1	1	1	NI L	1×10 <sup>1</sup>
13	TNT C	TNT C	TNT C	TNT C	117.3 3	89.67	117.33×10 5	TNT C	77	15	NI L	77×10 <sup>2</sup>
14	TNT C	TNT C	TNT C	TNT C	127.3 3	47.00	127.33×10 5	TNT C	31.5	11	NI L	31.5×10 2
15	TNT C	TNT C	105.0 0	28.33	NIL	NIL	105.00×10 3	TNT C	37.5	5	4	37.5×10 2
16	TNT C	TNT C	195.3 3	92.00	25.67	NIL	195.33×10 3	TNT C	94	9	NI L	94×10 <sup>2</sup>
17	TNT C	TNT C	143.0 0	52.67	9.33	NIL	143.00×10 3	58.5	7	1.5	NI L	58.5×10 1
18	TNT C	TNT C	TNT C	TNT C	69.33	26.00	69.33×10 <sup>5</sup>	59	12.5	1	NI L	59×10 <sup>1</sup>
19	TNT C	147.3 3	41.00	3.00	NIL	NIL	147.33×10 2	2.5	NIL	NIL	NI L	2.5×10 <sup>1</sup>
20	TNT C	TNT C	170.3 3	51.00	11.33	5.00	170.33×10 3	34.5	NIL	NIL	NI L	34.5×10 1
21	TNT	TNT	TNT	TNT	TNT	67.67	67.67×10 <sup>6</sup>	20.5	3	1	NI	20.5×10



	C	C	C	C	C						L	1
22	TNT C	TNT C	TNT C	TNT C	TNT C	58.33	58.33×106	15.5	10	1.5	NI L	15.5×10 1
23	TNT C	TNT C	132.0 0	73.67	15.67	NIL	132.00×10 3	23	2	NIL	NI L	23×101
24	TNT C	TNT C	167.0 0	73.33	27.67	5.00	167.00×10 3	24	17	7	NI L	24×101
25	TNT C	TNT C	TNT C	TNT C	70.33	30.33	70.33×105	5	NIL	NIL	NI L	5×101
26	TNT C	TNT C	192.3 3	163.6 7	45.00	NIL	192.33×10 3	68	11	NIL	NI L	68×101
27	TNT C	TNT C	82.00	41.67	8.00	NIL	82.00×103	79.5	11.5	3	NI L	79.5×10 1
28	TNT C	TNT C	TNT C	TNT C	64.00	30.33	64.00×105	TNT C	56	11	2	56×102
29	TNT C	TNT C	154.6 7	99.00	16.67	NIL	154.67×10 3	63.5	2	1	NI L	63.5×10 1
30	TNT C	TNT C	159.6 7	77.00	NIL	NIL	159.67×10 3	19	8.5	2.5	10	19×101
31	TNT C	TNT C	110.3 3	75.00	28.67	NIL	110.33×10 3	TNT C	36.5	12.5	1	36.5×10 2
32	TNT C	TNT C	TNT C	TNT C	TNT C	63.67	63.67×106	25	1	NIL	NI L	25×101
33	TNT C	TNT C	147.0 0	94.33	28.00	NIL	147.00×10 3	17.5	5	NIL	NI L	17.5×10 1
34	TNT C	TNT C	TNT C	163.3 3	63.33	10.00	163.33×10 4	5.5	NIL	NIL	NI L	5.5×101
35	TNT C	TNT C	TNT C	109.6 7	73.67	8.67	109.67×10 4	TNT C	31	4	NI L	31×102
36	TNT C	TNT C	TNT C	TNT C	TNT C	63.00	63.00×106	14.5	16	NIL	NI L	16×102
37	TNT C	TNT C	167.3 3	84.33	33.67	NIL	167.33×10 3	17.5	4.5	2	NI L	17.5×10 1
38	TNT C	TNT C	140.0 0	47.00	6.67	NIL	140.00×10 3	47	3.5	NIL	NI L	47×101
39	TNT C	TNT C	141.3 3	52.33	15.00	NIL	141.33×10 3	14	1	NIL	NI L	14×102
40	TNT C	112.0 0	49.00	14.67	NIL	NIL	112.00×10 2	72	3.5	5	NI L	72×101
1	TNT C	172.3 3	36.00	8.33	NIL	NIL	172.33×10 2	3	NIL	NIL	NI L	3×101

(Abbreviation: TNTC=Too Numerous to Count and CFU= Colony Forming Unit)